← Search another drug
PatientPulse · by PatientPartner
Jardiance empagliflozin
High confidence
~400 individual patient comments and reviews plus ~59 public pages analyzed (includes Drugs.com 369-review database, WebMD 147 reviews, AskaPatient 60 ratings, and forum discussions across Mayo Clinic Connect, Diabetes UK, DiabetesForum.com, and general public forums)
Executive intelligence
The signal that moves starts & adherence
35%Positive sentiment in discussion
64,248FDA adverse-event reports
61%Flagged serious
46%Reports name female patients
Genital mycotic infections are the single largest adherence-killer for Jardiance, mentioned in nearly 1 in 5 patient reviews, yet the label buries them below DKA in salience, creating a preventable expectation gap that peer mentorship can close before week two.
- Yeast and urinary infections drive the majority of early discontinuations, named by roughly 20 percent of reviewers, yet most patients report no advance warning from their prescriber.
- Weight loss and A1C improvement are powerful retention drivers for tolerators, with some patients reporting 30-plus-pound losses and dramatically improved glucose control within months.
- Cost and insurance access are a parallel discontinuation pathway, with patients reporting retail prices of $440 to $600 per 90-day supply and active cross-border pharmacy workarounds.
- The cardiac and renal protection narrative is gaining patient-level traction, with heart-failure and CKD patients specifically seeking Jardiance and reporting improved exercise tolerance and quality of life.